Objectives: To assess the inter-individual and intra-individual plasma concentration variabilities of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) in routine clinical practice and to investigate their relationships with virological failure.
Introduction
Combination antiretroviral therapy (cART) has markedly changed the prognosis of HIV-infected patients, reducing AIDS-related morbidity and mortality. 1 Despite its success, cART still lacks sufficient potency and durability: in fact, in a proportion of patients, antiretroviral regimens fail to suppress viral replication in the long term. 2 Reasons for treatment failure are multifactorial and may include poor adherence, development of antiviral resistance and pharmacokinetic factors. On the basis of the existence of plasma concentration-response and concentration-toxicity correlation for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), therapeutic drug monitoring (TDM) has been proposed to optimize the exposure to these agents. 3 In fact, differences in drug absorption, distribution, metabolism and elimination among individuals can determine variable plasma PI and NNRTI concentrations: 4 -7 antiretroviral drug levels may drop below effective concentrations, promoting treatment failure and selection of drug-resistant virus. Moreover, drug-drug or drug-food interactions may also contribute to inter-individual variability. 8 A further requirement for the feasibility of TDM in clinical practice is a low intra-individual variability. Factors that may influence intra-individual variability could be food interactions, concomitant medications, inaccurate reporting of medication timing and non-adherence with regular drug intake. 3 However, data on intra-individual variability of antiretroviral drug concentrations are scarce and additional studies are required to address this issue. 4, 9, 10 Results of randomized trials evaluating the clinical benefit of TDM in patients undergoing treatment for HIV are controversial. 11 -17 As a consequence, TDM is only recommended in particular clinical scenarios where drug concentrations are difficult to predict such as for the management of drug interactions, in patients with liver impairment, in patients with malabsorption, during pregnancy and in children. 18 We aimed to assess the inter-individual and intra-individual pharmacokinetic variabilities of NNRTI and PI concentrations in routine clinical practice. Furthermore, we investigated the occurrence of subtherapeutic drug concentrations, their correlates and relationships with subsequent virological failure to assess the potential relevance of routine TDM use in the clinical management of patients receiving cART.
Materials and methods

Patients
We performed an observational retrospective cohort study. We enrolled all HIV-infected patients who underwent TDM of NNRTI and PI plasma concentrations during routine outpatient visits from 1 January 2006 to 31 December 2007 at the Infectious Diseases Clinic of the 'Agostino Gemelli' hospital in Rome, Italy (cohort of 1625 HIV-infected patients of which 1371 on antiretroviral therapy at study time). To be eligible, patients had to: (i) be receiving a PI or NNRTI as a component of a cART regimen for at least 4 weeks, in order to allow for measurement of steady-state plasma antiretroviral concentrations; and (ii) have a measured trough concentration (C trough ), or mid-dosing interval concentration for atazanavir or efavirenz given at bedtime. Patients treated with darunavir were excluded from this analysis given that minimum effective concentrations for this agent have not yet been established. All patients at the clinical centre gave written, informed consent to be included in observational studies. This informed consent was approved by the local institutional Ethics Committee.
At study entry, all patients were treated with dosages currently recommended for NNRTIs and boosted or unboosted PIs, 19 with the exception of two patients with hepatic impairment who were taking unboosted saquinavir 1000 mg twice daily. The following demographic, clinical and laboratory variables were collected for each subject at the time of TDM sampling (baseline): gender, age, weight, ethnicity, co-infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), conditions that may impair drug exposure ( pregnancy, cirrhosis, renal and gastrointestinal impairment), risk factors for HIV infection, previous exposure to suboptimal therapy (defined as an antiretroviral therapy based on a single or dual agents), previous virological failure, history of AIDS-defining events, current antiretroviral regimen, concomitant medications, CD4 cell count and HIV-1 RNA load. All subsequent viral load measurements until 48 weeks after baseline were also collected. When available, we analysed the genotypic resistance test performed before TDM and interpreted it according to the ANRS interpretation system (version 17).
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Blood sampling for TDM The TDM service was systematically available, but since this study was conducted in the clinical practice and TDM request was left to the judgement of individual clinicians, criteria for using TDM could differ. In our department, TDM results are reported to clinicians together with the time of blood sampling and last drug intake. Results are interpreted based on clinical and viro-immunological data: the expert advice of a clinical pharmacologist is always available upon request of the treating clinician. Generally, when subtherapeutic drug levels are found, adherence counselling is performed and drug interactions are checked. Drug levels can then be re-evaluated and a dose adjustment is considered if low levels are still present.
Blood was collected before the morning antiretroviral drug intake to measure C trough and the time of the last drug intake and of blood sampling were recorded for each patient. In the case of patients taking efavirenz or atazanavir in the evening hours, middosing interval samples were also collected.
To evaluate pharmacokinetic variability, only samples collected 12+2 or 24+2 h after the last treatment intake were considered in patients taking drugs twice or once daily, respectively. Nevertheless, when efavirenz or atazanavir were administered at bedtime, samples collected 12+2 h after the drug intake were also analysed: however, in this case, pharmacokinetic variability was measured separately from the levels measured 24+2 h after drug intake.
Determination of plasma drug levels
Drug levels were measured by a validated HPLC-UV method, 21 modified for the quantification of all investigated antiretroviral drugs (limit of quantification 0.05 mg/L).
Briefly, blood samples (5 mL) were drawn into EDTA tubes and transported on ice to the laboratory, then immediately centrifuged for 10 min at 2000 g at 48C. Plasma was decanted and stored at 2208C until analysis.
For the preparation of internal quality controls (QCs) used for the validation of the assay, independent stock and working solutions containing the compound of interest were prepared and spiked in blank human plasma to achieve concentrations of 50, 500 and 5000 ng/mL (low, medium and high concentration, respectively). Validation of the assay was performed during 5 separate days. Accuracy of the assay was defined as the difference between the mean values of the QC samples and the expected value; in our system, such a difference was ,15% for the 500 and 5000 ng/mL concentrations and ,20% for the 50 ng/mL concentration, for both intra-and inter-assay variabilities. The precision of the assay was defined by the coefficient of variation (CV) calculated for each level of QC concentration in intra-and inter-assay tests; we found CV values consistently ,15%, or ,20% in the case of the low QC level. These results met the FDA criteria of acceptability for accuracy and precision of bioanalytical methods. 22 The accuracy of the present method was also repeatedly estimated from the analysis of four sets of two unknown samples of external QCs from the INSTAND e.V. (Duesseldorf, Germany) (WHO Collaborating Centre for Quality Assurance and Standardization in Laboratory Medicine), a QC programme for antiretroviral drugs.
Definition of therapeutic drug levels
Based on previously published data, drug concentrations were considered therapeutic if they were above the proposed minimum efficacy trough concentration: 1.0 mg/mL for efavirenz, 3.0 mg/mL for nevirapine, 0.15 mg/mL for atazanavir, 0.40 mg/mL (measured as amprenavir concentration) for fosamprenavir, 0.10 mg/mL for indinavir, 1.0 mg/mL for lopinavir, 0.80 mg/mL for nelfinavir, 0.10 mg/mL for saquinavir and 20.5 mg/mL for tipranavir. 19 For atazanavir administered at bedtime and measured in the morning (C 12 ), a previously validated efficacy threshold of 0.23 mg/mL was chosen, as described. 23 Ritonavir was only administered in a boosting (nontherapeutic) dose and was not included in the analysis.
Statistical analysis
Categorical variables were compared with the x 2 test or, when appropriate, Fisher's exact test; for continuous variables, comparisons were based on the non-parametric Mann-Whitney U-test.
Inter-individual and intra-individual pharmacokinetic variabilities were evaluated through the CV calculated as the quotient of the standard deviation divided by the mean plasma concentration Â100. In the calculation of pharmacokinetic variability, drug measurements below the lower limit of quantification of the assay (,0.05 mg/L) were arbitrarily considered as having a concentration of 0.04 mg/L.
For virological failure, the time-to-event analysis was performed using the Kaplan-Meier method. Follow-up was truncated at the time of virological failure, the date of interruption of the monitored drug, the date the patient had their last viral load measured or at 48 weeks after baseline, whichever occurred first. In the main analysis, virological failure was defined as not achieving a viral load ,50 copies/mL after 24 weeks of follow-up in patients with detectable (.50 copies/mL) baseline HIV-RNA levels; patients with undetectable viral load were considered to fail in case of a rebound to .1000 copies/mL on a single occasion or to .200 copies/mL on at least two consecutive instances. In the latter case, the date of the first viral load .200 copies/mL was used as the date of failure. In a subgroup analysis, we selected only patients with baseline HIV-RNA ,200 copies/mL: the same criteria for virological failure were employed.
Univariate and multivariate Cox's regression models were used to investigate predictors of virological failure. All variables tested in the univariable model were included in the multivariable analysis. For the association between drug level and virological response, when more than one plasma concentration was available for the same patient, we considered each sample separately and evaluated the subsequent 48 weeks virological response in each instance. However, we also performed a sensitivity analysis evaluating only the first sample of a patient or using the average concentration of multiple samples from each patient.
A two-tailed P value of ,0.05 was considered statistically significant. All analyses were performed using the SPSS Version 13.0 software package (SPSS Inc., Chicago, IL, USA).
Results
Patients' characteristics and plasma drug concentrations
From January 2006 to December 2007, TDM was performed in 448 out of the 1371 patients on antiretroviral therapy in our cohort. Of these, 73 were excluded because their drug level measurement did not correspond to the definitions required for C trough measurement (or C 12 for efavirenz and atazanavir) and 12 because they only monitored darunavir plasma levels. Finally, a total of 629 plasma antiretroviral concentrations meeting the selection criteria were measured in 363 patients (26.5% of the total number of patients on antiretroviral therapy in our cohort). drug was found in 15.4% (n ¼ 49) of these, according to the ANRS interpretation system. Drug concentration was optimal in 83.1% of the cases; subtherapeutic concentration was observed in 106 measurements (16.9%), including 47 (7.5%) in which drugs were below the limit of detection. After the detection of subtherapeutic drug levels, treatment changes were performed in only 11 of the 106 (10.4%) cases (4 dose adjustments and 7 drug substitutions).
Inter-individual and intra-individual drug concentration variabilities
Inter-individual variability was evaluated in a subset of 541 drug measurements: 232 determinations were performed on samples collected 12+2 h after the last treatment intake for twice-daily regimens and 68 on samples collected 24+2 h for once-daily regimens; in addition, 111 efavirenz and 130 atazanavir measurements were performed 12+2 h after the last intake because the drugs were administered at bedtime. Inter-individual coefficients of variation (CV inter ) are shown in Table 2 . Overall, a high inter-individual variability was observed. When drugs were categorized according to classes, NNRTIs showed less inter-individual variability than PIs fmedian CV inter 54.8% [inter-quartile range (IQR) 52.5-70.0] versus 84.3% (IQR 79.8 -127.5), respectively; P ¼ 0.102g.
When more than one measurement of the same drug was available for the same patient, intra-individual pharmacokinetic variability was evaluated. The median interval between the first and the last measurement used to calculate intra-individual variability was 9 months (IQR 4 -13). Table 2 shows median intra-individual coefficients of variation (CV intra ) for each drug. NNRTIs showed less intra-individual variability than PIs: median CV intra 19.0% (IQR 10.4-40.4) versus 38.1% (IQR 15.3 -73.8), respectively (P ¼ 0.011). Intra-individual variability was lower than inter-individual variability: comparing both drug classes and each drug, CV intra appeared constantly lower than CV inter (Table 2) .
Correlates of therapeutic drug concentrations
Patients' demographic and clinical characteristics, split according to the presence of subtherapeutic or therapeutic drug levels, are shown in Table 3 . In a univariate analysis, older age (P ¼ 0.020) and higher contemporary viral load (P ¼ 0.013) were statistically associated with subtherapeutic levels. When TDM was performed, patients with therapeutic levels had a viral load of ,50 copies/mL more frequently than those with subtherapeutic levels (74.8% versus 63.2%, P ¼ 0.020). No statistically significant differences across the two groups were observed with regard to gender, weight, ethnicity, HBV/HCV co-infection, pregnancy, concomitant use of cytochrome P450 inducers or gastric acid-reducing agents. Of note, in the only patient with documented malabsorption (Crohn's disease), the drug level was suboptimal.
Therapeutic concentrations were observed in 154 (89.5%) NNRTI measurements and in 369 (80.7%) PI measurements (P ¼ 0.012). Both NNRTIs and boosted PIs reached optimal plasma levels in a significantly higher percentage than unboosted PIs (89.5% and 85.9% versus 60.5%, respectively; P, 0.001 for each comparison). Among the samples with subtherapeutic concentrations, drugs were below the limit of detection in near half of the cases (47/106, 44.3%) and PIs were more frequently undetectable than NNRTIs (45/88, 51.1% versus 2/18, 11.1%, P ¼ 0.004). Table 4 gives proportions of measurements showing therapeutic and subtherapeutic levels for each drug. Therapeutic concentrations were reached most frequently by efavirenz (89.9%) and less frequently by tipranavir (50.0%). Efavirenz and lopinavir achieved optimal levels more often than atazanavir, saquinavir and tipranavir (89.9% and 89.3% versus 79%, 62.5% and 50.0%, respectively, P,0.05). For single PI drugs, those boosted with ritonavir were prone to achieve therapeutic levels more frequently than those without ritonavir boosting; in particular, statistically significant differences were observed for atazanavir versus atazanavir/ritonavir (60.0% versus 87.4% therapeutic levels, respectively, P,0.001).
Predictors of virological response
A follow-up was available in 589 instances: virological failure occurred in 17.1% of these with a median time to virological failure of 17 weeks (range 0 -48). The association of drug exposure with subsequent time to virological failure is illustrated in Figure 1 . In the whole population, the estimated proportion with virological failure at 24 weeks was 0.21 in patients with suboptimal baseline drug levels and 0.08 in those with optimal plasma levels (log-rank test: P,0.001) (Figure 1a ). In the subgroup of patients with baseline viral load ,200 copies/mL (n ¼ 491), the estimated proportion with virological failure at 24 weeks was 0.09 in patients with suboptimal baseline drug levels and 0.03 in those with optimal plasma levels (log-rank test: P ¼0.012) (Figure 1b) . Predictors of virological failure were investigated by Cox's regression model (Table 5) . In a univariate analysis, non-Italian born patients, Black African versus Caucasian ethnicity, injecting drug users, patients with a longer time from HIV diagnosis, those with a history of AIDS-defining events, those with previous exposure to suboptimal therapy, those on a more advanced treatment line and higher baseline viral load showed a higher risk of virological failure. Conversely, older patients, those with no genotypic resistance test previously performed, those on NNRTI-based as compared with boosted PI-based regimens, those with higher CD4 cell count and with therapeutic drug levels showed a lower risk of virological failure. In the multivariate analysis, history of AIDS-defining events, the use of stavudine þ lamivudine as compared with tenofovir þ lamivudine or emtricitabine as NRTI backbone, the use of a boosted PI-based regimen and higher viral load showed an independent association with virological failure, while older age and therapeutic drug levels conveyed a lower risk of virological failure. Optimal drug levels were confirmed to be independent negative predictors of virological failure also in the subgroup of patients with baseline HIV-RNA ,200 copies/mL [adjusted hazard ratio (aHR) 0.434, 95% confidence interval (CI) 0.218 -0.865,
In sensitivity analyses, using only the first sample or the average concentration of multiple samples from each patient, results were comparable to those reported in the main analysis: first sample results, therapeutic versus subtherapeutic levels, aHR 0.401, 95% CI 0.230 -0.702, P ¼ 0.001; average concentration aHR 0.456, 95% CI 0.225 -0.816, P ¼ 0.008.
Discussion
The demonstration of a relationship between plasma levels of PIs and NNRTIs and their efficacy or toxicity suggests that monitoring the concentrations of these drugs can be useful for the clinical management of patients on cART. However, clinical trials evaluating TDM implementation have shown conflicting results: in fact, in patients undergoing TDM-driven interventions, a significantly higher virological suppression rate, demonstrated in some studies, 11, 12 has not always been confirmed. 13 -17 This highlights the need for new studies to explore this approach.
We analysed the use of TDM in the clinical practice in a large cohort of HIV-infected outpatients, represented mainly by subjects with a virologically and immunologically controlled disease. Since clinicians could be more likely to seek TDM in patients who are suspected of having altered drug levels (e.g. for Pharmacokinetic variability of antiretroviral drugs poor adherence, drug interactions, liver impairment or other concomitant illnesses), the study design could have introduced potential sources of biases that must be considered when interpreting our results. Nonetheless, the data obtained can add further scientific support to the use of TDM in the clinical practice.
In the studied population, the majority of patients (83.1%) had therapeutic drug levels. However, subtherapeutic concentrations were detected in 16.9% of samples: these subjects showed an HIV-RNA ,50 copies/mL in a lower proportion than those with therapeutic levels. In these circumstances, viral replication, even at a low level, can increase the risk of developing drug resistance, promoting treatment failure and limiting the future use of antiretrovirals.
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In our population, unboosted PI plasma levels were more frequently suboptimal than ritonavir boosted PIs and NNRTIs. Unboosted PI regimens are used in certain patient categories to decrease adverse events, but these subjects are more prone to develop low plasma concentrations with a higher risk of virological failure. Therefore, TDM can be particularly useful in this setting where inter-individual pharmacokinetic variability is particularly striking. When only samples with subtherapeutic drug concentrations were considered, PIs were more frequently undetectable than NNRTIs. This is in part due to the pharmacokinetic properties of NNRTIs that have a long half-life and can be found in plasma even days after the intake of the last dose.
25 HIV treatment requires the concomitant use of multiple drugs for sustained viral suppression but, when TDM is performed using plasma samples, only the concentration of selected agents (PIs or NNRTIs) is usually monitored: this may not be adequate under all circumstances. However, we found a strong association between subtherapeutic plasma concentrations and higher rates of virological failure during follow-up. Moreover, when analysing predictors of virological outcome, optimal drug levels were independently associated with a lower risk of virological failure. We investigated several factors thought to influence inadequate exposure to antiretroviral drugs. The lack of association between antiretroviral concentrations and investigated features (gender, ethnicity, body weight, injection drug use, pregnancy, HBV or HCV co-infection) shows that, in clinical practice, it is often difficult to identify patients predisposed to developing low plasma drug levels, suggesting the utility of routine TDM to improve cART success. We also investigated whether the use of cytochrome CYP3A4 inducers or acidreducing agents could affect drug concentrations in our population and found no associations with the development of subtherapeutic drug levels (Table 3 ). However, this study was not designed to assess drug interactions in detail and from our data we can only conclude that medications potentially interacting with the measured drug were administered in 9/106 (8.5%) cases with subtherapeutic levels and in 34/523 (6.5%) cases with therapeutic levels.
An important factor contributing to the prevalence of suboptimal plasma concentrations in our cohort may have been an incomplete adherence to the prescribed therapy. In fact, nearly half of all samples designated as subtherapeutic exhibited no trace of drugs. Since our study was conducted retrospectively in clinical practice, we could not assess the degree of adherence. However, TDM has been claimed as an objective, although incomplete, method to determine adherence and it may be helpful for this purpose especially if used in conjunction with other tools ( patients self-reporting, pill counts, pharmacy records and electronic monitoring).
A potential limitation of our study is that we could not adjust efficacy thresholds for individual drugs based on previously selected drug resistance mutations. In subjects harbouring partially resistant viral strains, thresholds used to define therapeutic range might have been inadequate, since reference concentrations for wild-type virus could be insufficient to suppress subpopulations with reduced susceptibility. However, current guidelines 18, 19, 26 do not include efficacy thresholds for patients harbouring partially resistant virus (with the exception of tipranavir) and no definite data are yet available on plasma drug minimum effective concentrations for those patients. We addressed whether reduced susceptibility to the measured drug could influence the association between therapeutic drug levels and subsequent virological failure in a multivariable analysis, but the adjusted association between drug levels and virological outcome was still statistically significant. Nonetheless, only a total of 7.8% of the studied cases' virus had some level of resistance to the measured drugs, therefore our results can be mainly applied to individuals carrying drug-susceptible virus. Prospective studies are needed to define the efficacy thresholds in patients harbouring drug-resistant viruses.
Many reports have demonstrated that, if antiretroviral concentrations are too low or too high, patients may have serious clinical consequences (i.e. insufficient virological response or development of toxicity). 4, 5, 27 Therefore, it is important to increase our knowledge about the extent of inter-individual pharmacokinetic variability in outpatient routine clinical settings and about factors that contribute to it. Our study confirmed high levels of inter-patient variability for all antiretroviral drugs. Of note, CV inter was more elevated for PIs than for NNRTIs. This inter-individual variability in drug concentrations can be explained by differences in absorption, distribution, metabolism and elimination among different patients. Moreover, poor adherence, concomitant diseases, drug interactions and food requirements could also have played roles, particularly for PIs.
Intra-individual pharmacokinetic variability is a critical issue in evaluating the utility of TDM. Since in the clinical practice it is often difficult to obtain multiple samples for drug measurement from the same patient, clinicians must assume that interday variation of drug levels in each subject is minimal. However, few studies have addressed this issue, sometimes with conflicting results, 4, 9, 10 and additional data are required, especially for recently introduced drugs. We found a limited intra-individual variability in our population, with lower values for NNRTIs than for PIs (CV intra 19.0% versus 38.1%). CV intra varied widely between drugs, with a minimum for nevirapine (16.3%) and a maximum for saquinavir (109.6%). Noteworthily, however, intra-individual variability was constantly lower than inter-individual variability for drug classes as well as for individual antiretrovirals: this observation is an important prerequisite for the feasibility of TDM in clinical practice.
In conclusion, TDM seems to be a promising strategy to increase the success of antiretroviral therapy but to date it has been applied only in selected groups of patients. Our findings about pharmacological features of antiretroviral drugs, such as wide inter-individual variability and limited intra-individual variability, together with the demonstration of a concentrationresponse relationship using pre-established efficacy thresholds, suggest that TDM is a useful monitoring tool for patients on PI or NNRTI therapy. However, well-designed trials are required in order to assess the potential utility of TDM-based intervention before it can be definitively recommended for routine clinical practice.
